Vaccination after hematopoietic stem cell transplantation : a randomized study estimating the interest of an additional injection for patients not reponding at M3. - EVaxAll

niversity Hospital Grenoble0 个研究点目标入组 200 人开始时间: 2018年3月15日最近更新: 2018年3月26日

适应症

试验速览

暂无简介。

•- Age greater than or equal to 18 years
•- Realization of an allograft of haematopoietic stem cells at least 6 months, and at the most 24 months before inclusion
•- Discontinuation of immunosuppressive therapy for at least 3 months
•- Absence of GVH superior to grade I at the initiation of vaccination
•- Informed Consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 200
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Pregnant, parturient or nursing women
•- Person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure, subject to administrative or judicial supervision
•- Patients who received supplementation in the last 3 months with multivalent immunoglobulins, or for whom this treatment is planned
•- Contra-indication to Infanrix hexa® (hypersensitivity during an earlier injection)
•- Fever (=38 ° C) during consultation (delays inclusion at 1 week)

发起方

niversity Hospital Grenoble